Investors

Bullpen is an invite-only club that gathers life science investors and senior executives with a shared goal of helping each other. The organization hosts a variety of events, including virtual panels, live events, and community gatherings, to facilitate networking and collaboration among top-tier life science deal makers. Bullpen emphasizes creating meaningful connections and fostering collaborations that lead to real-world impact.

New Science Ventures, LLC (NSV) is a venture capital firm based in Connecticut and London. The firm invests in early and late-stage companies that employ novel scientific approaches to address significant unmet needs in the life sciences and information technology sectors. NSV focuses on creating value through breakthrough science, leveraging its extensive experience and networks in these industries.

Brightstone Venture Capital manages a $100 million venture fund focused on early-growth stage investment opportunities. The firm leverages the deep operating experience and successful investment background of its partners, primarily focusing on investing in technology and life sciences sectors. Brightstone aims to help extraordinary entrepreneurs build exceptional companies by providing strategic guidance and capital to drive growth and innovation.

New Mexico Angels is a premier organization of angel investors dedicated to supporting start-up and high-growth companies in New Mexico and the Southwest Region. Their mission is to provide opportunities for members to achieve outstanding financial returns by investing in early-stage companies and accelerating them to market leadership. The organization collaborates with the venture capital community and angel groups in the Southwestern area to bring in important next financing rounds.

Propel Bio Partners is a venture capital firm dedicated to advancing human health by investing in life science companies. The firm leverages its expertise in science and business to support founders in developing disruptive therapies and technologies. Propel Bio Partners builds ecosystems to help founders achieve their vision, focusing on groundbreaking technologies and therapies that improve human health.

Kreos Capital is a leading provider of growth debt financing for high-growth companies across Europe and Israel. The firm focuses on supporting companies in various stages of development, providing them with the necessary capital to scale and succeed in their respective industries.

i&i Biotech Fund (i&i Bio) is a Luxembourg-based venture capital firm that invests in innovative European Life Sciences companies focused on drug discoveries, medical devices, diagnostics, and digital health. The fund was established in cooperation with the biotech incubator i&i Prague and the European Investment Fund. With over €53 million under management, i&i Bio plans to invest in about 20 early-stage companies, supporting transformative Central European technology companies.

Riverfront Ventures is an early-stage venture capital firm based in Pittsburgh, PA, focused on investing in early-growth stage tech companies. As the venture capital arm of Innovation Works, Riverfront Ventures leverages its experience and resources to support startups in technology sectors with large market potential. The firm co-invests with top venture firms to help startups scale, providing guidance through funding, team building, and strategic partnerships. Riverfront Ventures is committed to driving Pittsburgh companies to succeed on a global stage, with a portfolio that spans software, life sciences, robotics, and more.

CSSi LifeSciences is a global, innovative CRO and consulting group specializing in advancing therapeutics and medical devices through development and regulatory approval. The company offers customized solutions to mitigate risk, time, and expense, supporting the U.S. market goals of its clients. CSSi LifeSciences is committed to accelerating the development of drugs and medical devices to market for patients who benefit most, providing strategic regulatory guidance to optimize programs at any stage from proof of concept through commercialization.

Epidarex Capital is a transatlantic venture capital firm focused on building breakthrough life science companies in emerging hubs. The firm leverages its deep scientific and industry networks to create exceptional value and shared success, catalyzing innovation in health science and technology.

Hatteras Venture Partners is a venture capital firm dedicated to building transformational human medicine companies that benefit patients and the professionals who serve them. With over two decades of experience, Hatteras focuses on early-stage investments in healthcare innovation, including biopharmaceuticals, medical devices, diagnostics, and healthcare IT. The firm is committed to improving health through transformative therapies and disruptive technologies.

Windham Capital Partners is a venture capital firm focused on investing in innovative HealthTech companies that are developing life-saving and game-changing technologies. The firm leverages its extensive network in the pharmaceutical, medical device, and digital health markets to build strategic relationships and support entrepreneurs in creating category-defining products. Windham Capital Partners is committed to investing in companies that address large unmet medical needs and have the potential to transform healthcare, ultimately providing significant returns to its investors.

Eiffel Investment Group is a dynamic and entrepreneurial asset management firm with a strong focus on sustainable investment. The firm manages approximately 7 billion euros in assets, serving large institutional investors and individual savers through distribution networks. With a commitment to the energy transition, Eiffel Investment Group invests in private debt, infrastructure equity, and listed credit and equities, aiming to generate both financial performance and positive environmental and social impacts. The group is backed by Impala, led by entrepreneur Jacques Veyrat, and has a strong industrial expertise, particularly in energy transition.

Novalis Biotech is an early-stage venture capital firm focused on life sciences, particularly in the realm of enabling technologies. The firm emphasizes capital-light platform technologies and close customer interaction from the early stages of a company's life. Novalis invests in innovative research and manufacturing tools, bioinformatics, genomics, diagnostics, and digital health, supporting early-stage startups from pre-seed to Series A. The firm aims to create value for stakeholders by providing funding, leveraging professional and academic connections, and shaping business strategies.

Inovia Capital is a full-stack venture capital firm dedicated to partnering with founders to build impactful and enduring global companies. With a focus on investments from pre-seed to pre-IPO, Inovia supports founders with capital, insights, and mentorship throughout their journey. The firm has been at the forefront of technology shifts since the internet and mobile era in the '90s and continues to back innovators in emerging technologies, including Generative AI. Inovia is committed to elevating founders, companies, and communities by mentoring, making connections, and opening doors, aiming to have a positive, lasting impact on the world.

Whiz Partners Inc. is a venture capital firm based in Minato-ku, Tokyo, Japan. The firm is known for its strategic investments in healthcare and technology sectors, leveraging its Whiz HealthCare Japan 2.0 Investment Limited Partnership and Whiz Asia Evolution Fund to support innovative companies. Whiz Partners aims to foster growth and development in its portfolio companies through strategic partnerships and investments.

Founded in 1999, Stonehenge Capital Company, LLC is a nationally recognized impact investor focused on providing transformational capital to lower middle market operating companies. The firm operates one of the largest and most successful federal and state New Markets Tax Credit practices in the industry, managing over $1.4 billion in investments across U.S. distressed communities. Stonehenge also provides traditional debt and equity financing through state-targeted small business investment funds, with over $400 million in Assets Under Management. The company is dedicated to investing in America by creating quality jobs, preserving historic buildings, supporting low-income communities, and building a more sustainable future.

Samsung Venture Investment Corporation, as the venture investment arm of the Samsung Group, is dedicated to driving the discovery and development of new businesses and technologies. The firm aims to promote an open innovation environment, anticipating global challenges and supporting the creation of new industries. Its mission is to be a global pioneering corporate venture capital (CVC) that contributes to society and the Samsung Group.

OMX Ventures is a venture capital firm that specializes in building scalable biotech companies using a technology-first approach. They focus on transformative technologies in the biotech sector, leveraging data from novel bio-tools, data, and artificial intelligence to create the next generation of medicines, tools, and solutions. Their mission is to support groundbreaking discoveries and grow them into scalable companies, particularly in the fields of therapeutics, bio-tools, diagnostics, and synthetic biology.

Okapi Venture Capital, established in 2005, is a seed and early-stage venture capital firm focused on technology startups primarily in Southern California. The firm prides itself on providing long-term capital and management support to its portfolio companies, leveraging its extensive network and the deep experience of its partners. Okapi's investment strategy emphasizes venture fundamentals, disciplined investment, and active engagement to optimize potential returns while minimizing risks. The firm is known for its hands-on approach, often taking lead or co-lead roles in investments, and its commitment to helping startups achieve significant milestones and prepare for subsequent funding rounds.